US11324758B2 - Formulation and process for limiting nerve trauma - Google Patents

Formulation and process for limiting nerve trauma Download PDF

Info

Publication number
US11324758B2
US11324758B2 US15/579,224 US201615579224A US11324758B2 US 11324758 B2 US11324758 B2 US 11324758B2 US 201615579224 A US201615579224 A US 201615579224A US 11324758 B2 US11324758 B2 US 11324758B2
Authority
US
United States
Prior art keywords
nerve
formulation
forms
exposed
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/579,224
Other versions
US20180185390A1 (en
Inventor
Timothy J. Eviston
Arun Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intravital Pty Ltd
Original Assignee
Intravital Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902089A external-priority patent/AU2015902089A0/en
Application filed by Intravital Pty Ltd filed Critical Intravital Pty Ltd
Assigned to NEWSOUTH INNOVATIONS PTY LIMITED reassignment NEWSOUTH INNOVATIONS PTY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVISTON, TIMOTHY J, KRISHNAN, ARUN
Publication of US20180185390A1 publication Critical patent/US20180185390A1/en
Assigned to INTRAVITAL PTY LTD reassignment INTRAVITAL PTY LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEWSOUTH INNOVATIONS PTY LTD
Application granted granted Critical
Publication of US11324758B2 publication Critical patent/US11324758B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/389—Electromyography [EMG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2422—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31593—Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
    • A61M5/31595—Pre-defined multi-dose administration by repeated overcoming of means blocking the free advancing movement of piston rod, e.g. by tearing or de-blocking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/48—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for varying, regulating, indicating or limiting injection pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3472—Trocars; Puncturing needles for bones, e.g. intraosseus injections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3933—Liquid markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3937—Visible markers
    • A61B2090/3941—Photoluminescent markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
    • A61B2505/05—Surgical care
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A61M2005/005—Magazines with multiple ampoules directly inserted into an injection or infusion device, e.g. revolver-like magazines containing ampoules with or without needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2477—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means to reduce play of ampoule within ampoule holder, e.g. springs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2481—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for biasing the ampoule out of the ampoule holder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3117—Means preventing contamination of the medicament compartment of a syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/13—General characteristics of the apparatus with means for the detection of operative contact with patient, e.g. lip sensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/10—Tube connectors; Tube couplings
    • A61M39/16—Tube connectors; Tube couplings having provision for disinfection or sterilisation
    • A61M39/18—Methods or apparatus for making the connection under sterile conditions, i.e. sterile docking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2455—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened
    • A61M5/2466—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened by piercing without internal pressure increase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
    • A61M5/3158—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod performed by axially moving actuator operated by user, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
    • A61M5/31581—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod performed by rotationally moving or pivoting actuator operated by user, e.g. an injection lever or handle

Definitions

  • the present invention relates to limiting trauma to a nerve, and to a formulation, delivery system and process for limiting trauma to a nerve.
  • the formulation and process particularly limit the impact of surgery or other event or activity on a nerve, however the formulation and process are not limited to those applications.
  • the delivery system is particularly suited to delivering a therapeutic substance during surgery but is not limited to that application
  • Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery.
  • the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
  • the therapeutic substance comprises an active pharmacological ingredient and a carrier.
  • the process has the benefit of limiting nerve trauma for patients during surgery or dental surgery by providing a predictable localisation and consistent rate-limited delivery of an active pharmaceutical ingredient that reduces the trauma on nerves through surgery.
  • the delivery of the active pharmaceutical ingredient directly to the nerve during surgery improves nerve function and repair post surgery.
  • a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
  • the formulation includes an active pharmaceutical ingredient and a carrier that provides benefits such as slow release and localisation of the active pharmaceutical.
  • the active pharmaceutical ingredient therefore is more likely to remain on the intended site of effect.
  • the use comprises applying the formulation to a nerve that has been exposed during surgery.
  • Disclosed in some forms is a method of delivering a therapeutic substance during surgery, the method comprising loading a solid phase or gel phase biodegradeable scaffold with a therapeutic substance; and positioning the scaffold during surgery such that the therapeutic substance is delivered to a desired location.
  • the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve and the desired location is proximal to a nerve.
  • the method allows for delivery of a therapeutic substance and a haemostatic agent in combination.
  • a system for delivering a therapeutic substance during surgery comprising a solid phase biodegradable scaffold with a therapeutic substance loaded thereon.
  • the method and system may provide for improved levels of pain management, improved delivery of the therapeutic substance, improved recovery, improved muscle function, improved autonomy, or improved sensation. In some forms chronic pain or inflammation can be reduced or avoided. In some forms delivery of the drug beyond a selected site is minimised.
  • the method of delivery allows differentiation of delivery of different therapeutic substances.
  • a formulation comprising an active pharmacological ingredient having a neuroprotective effect and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
  • a process of protecting a nerve during surgery comprising identifying a nerve using a nerve monitor and applying a therapeutic substance to the nerve.
  • the process further comprises the step of monitoring the nerve function by monitoring EMG activity from muscles innervated by the affected nerve.
  • the process, formulation and delivery system may provide for improved levels of pain, improved recovery, improved muscle function, improved autonomy, or improved sensation. In some forms chronic pain or inflammation can be reduced or avoided. They may provide for improved effectiveness of treatment.
  • FIG. 1 is a graphical representation of molecular weight v time for hyaluronic acid with dexamethasone as in some embodiments of the disclosure
  • FIG. 2 is a graphical representation of molecular weight v time for hyaluronic acid with dexamethasone as in some embodiments of the disclosure
  • FIG. 3 graphical representation of drug stability v time for dexamethasone in the presence of excipients as in some embodiments of the disclosure
  • FIG. 4 is a graphical representation of drug stability v time for dexamethasone with hyaluronic acid as in some embodiments of the disclosure.
  • Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery.
  • the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve. In some forms the formulation interrupts or downregulates intra-axonal pathways of cell death or degradation during the course of a surgical procedure. In some forms the therapeutic substance has a neuroprotective effect.
  • the therapeutic substance comprises an active pharmacological ingredient and a carrier.
  • the carrier is a depot matrix. In some forms the carrier is adapted to slow the release of the active pharmacological ingredient.
  • the carrier has a consistency and rheology adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
  • the carrier is adapted to localise the active pharmacological ingredient to the site at which its effect is intended.
  • the active pharmacological ingredient is a corticosteroid. In some forms the pharmacological ingredient is dexamethasone.
  • the active pharmacological ingredient is hydrocortisone, methylprednisone, triamcinolone, Betamethasone or any other corticosteroid.
  • the active pharmacological ingredient is any of a number of medications which have a neuroprotective effect or act to decrease nerve dysfunction.
  • This may include any one or more of 4-Aminopyridine (or derivatives eg. Fampridine), Riluzole, NAD altering molecules such as nicotinamide mononucleotide, CD38 and cyclic ADP ribose hydrolase inhibitors, nicotinomide riboside, AICAR, resveratrol, thiazolidinediones (eg. rosiglitazone, pioglitazone etc), metformin, local anaesthetics (eg.
  • bupivicaine cyclosporin
  • tacrolimus COX inhibitors (eg. ketorolac, diclofenac), calcium channel blockers (eg. nifedipine), pipaverine, dexpramiprexole.
  • COX inhibitors eg. ketorolac, diclofenac
  • calcium channel blockers eg. nifedipine
  • pipaverine dexpramiprexole.
  • the active pharmacological acts by improving mitochondrial function or inhibiting calcium or cell death pathways.
  • Nerve injury peripheral to the surgery is a danger of surgery. Nerve dysfunction can result from trauma to the nerves despite the nerves appearing to be intact. This makes nerve dysfunction difficult to predict during surgery. Traumatic mechanisms such as stretch, thermal injury, electrical injury, compression and ischaemia can accumulate to cause activation of pathways of cellular degradation within a nerve's axon. This can cause nerve break down and loss of function.
  • the step of applying a therapeutic substance to the nerve is performed upon exposure of the nerve during surgery.
  • the step of applying a therapeutic substance to the nerve is performed using a delivery device comprising a reservoir and an outlet, the therapeutic substance being delivered through the outlet.
  • actuation of the delivery device effects delivery of the formulation during the time at which the actuator is actuated.
  • a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to slow release to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended.
  • the active pharmacological ingredient is effective to limit nerve dysfunction or have a neuroprotective impact.
  • the active pharmaceutical ingredient may also include a prodrug, biologic, immunoglobulin, viral vector, gene therapy, immunotherapy, DNA plasmid, RNA inhibitor or protein or peptide.
  • the formulation allows the application of an active pharmaceutical ingredient to a nerve while limiting the application of that ingredient to surrounding cells. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste.
  • the formulation can also act to slow release of the active pharmaceutical ingredient.
  • the formulation in some embodiments of the disclosure, comprises a corticosteroid such as dexamethasone in the form of dexamethasone phosphate or dexamethasone sodium phosphate in hyaluronic acid.
  • the formulation comprises dexamethasone sodium phosphate, in a hydrogel of hyaluronic acid.
  • the formulation further includes any one of more of the excipients creatinine, sodium citrate, sodium sulphate, methyl paraben, propylparaben.
  • the hyaluronic acid may be cross-linked using a process such as divinyl sulfone or similar cross-linking technology.
  • the hyaluronic acid may be esterified.
  • the formulation includes a marker such as a visual or fluorescent marker.
  • a marker such as a visual or fluorescent marker.
  • Example markers could include biocompatible excipients or food dyes such as brilliant blue (FD&C Blue #1), indigo carmine or similar, antioxidants such as ascorbic acid, fluorescent markers such as Fluorescein, indocyanine green (ICG), protoporphyrin IX or other surgical dyes such as patent blue V, trypan blue, isosulfan blue or methylene blue.
  • FD&C Blue #1 brilliant blue
  • ICG indocyanine green
  • protoporphyrin IX protoporphyrin IX or other surgical dyes such as patent blue V, trypan blue, isosulfan blue or methylene blue.
  • the use of a marker gives a surgeon a visual cue to indicate the presence of the formulation on a nerve. This may aid the user in applying the formulation under-vision and to prevent repeated dosing over the same site. In some forms this enables the future identification
  • the use comprises applying the formulation to a nerve that has been exposed during surgery.
  • composition comprising hyaluronic acid and dexamethasone.
  • the composition in some forms is for use in the treatment and protection of nerves during surgery.
  • the hyaluronic acid is in the concentration of between 1% and 3% w/w. In some forms the concentration of hyaluronic acid is between approximately 10 mg/mL and 50 mg/mL, in some forms the concentration is 30 mg/mL.
  • the hyaluronic acid is in the form of sodium hyaluronate with a Molecular weight of 0.9 MDa (0.8-1.0) or a molecular weight of 2.1 MDa (2.0-2.3 MDa) But may be within the range 7 to 2300 kDa.
  • the formulation comprises hyaluronic acid with a substantially consistent molecular weight of approximately 0.9 MDa or a substantially consistent molecular weight of approximately between 0.8 and 1.0 MDa.
  • the formulation may have a concentration of approximately 5% w/w.
  • the formulation may include dexamethasone at a concentration of approximately 1 mg/mL.
  • the formulation comprises hyaluronic acid with a substantially consistent molecular weight of approximately 2.1 MDa or a substantially consistent molecular weight of approximately between 2.0 and 3.0 MDa.
  • the formulation may have a concentration of approximately 3% w/w.
  • the formulation may also include dexamethasone at a concentration of approximately 1 mg/mL.
  • the carrier may be an oligosaccharide of sodium hyaluronate. In some forms the carrier may be a sodium hyaluronate nanofiber or microfiber.
  • the carrier has a consistent molecular weight and a consistent concentration.
  • a consistent molecular weight in combination with a consistent concentration results in a reproducible viscosity and rheology.
  • the dexamethasone is in the form of dexamethasone phosphate. In some forms the dexamethasone phosphate is in the concentration of between 0.1 mg/mL and 10.0 mg/mL. In some forms the dexamethasone phosphate is in the concentration of approximately 1 mg/mL. In some forms the dexamethasone phosphate is in a concentration of 4 mg/mL.
  • the hyaluronic acid has a weight percentage between 0.5% and 5% w/w. In some forms the weight percentage of hyaluronic acid in the formulation is between 1% and 3%. In some forms the weight percentage of hyaluronic acid in the formulation is approximately 2%.
  • the dexamethasone is in the form of dexamethasone sodium phosphate. In some forms the dexamethasone sodium phosphate is in the concentration of between 0.5 mg/mL and 4.0 mg/mL. In some forms the dexamethasone sodium phosphate is in the concentration of approximately 1 mg/mL.
  • composition further comprises one or more of creatinine, sodium citrate, sodium disulfite, methyl paraben, propyl paraben.
  • composition comprising hyaluronic acid and dexamethasone in the manufacture of a medicament for treatment and protection of nerves during surgery.
  • a composition comprising:
  • a pharmacological active having one or more of a neuroprotective effect and a reduction of nerve dysfunction
  • the rheology of the matrix limits the flow of the active away from a site of delivery. In some forms this allows for extended therapeutic effects. In some forms the elastic modulus of the matrix is between 100-200 Pa.
  • the carrier or matrix is adapted to slow release, to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste.
  • the method comprises using a delivery device to deliver the composition.
  • the method is used in conjunction with a nerve monitor to enhance the process of locating a particular nerve and allow accurate deposit of the therapeutic formulation to the nerve.
  • a nerve monitor to enhance the process of locating a particular nerve and allow accurate deposit of the therapeutic formulation to the nerve.
  • This provides a complete nerve solution by utilising both a diagnostic tool and a therapeutic formulation to treat and protect a nerve.
  • Nerve monitors enable surgeons to identify, confirm, and monitor motor nerve function to help reduce the risk of nerve damage during various procedures.
  • the method comprises loading a solid phase biodegradable scaffold with a therapeutic substance; positioning the scaffold during surgery such that the therapeutic substance is delivered to a desired location.
  • the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
  • the desired location is proximal or adjacent to a nerve.
  • the therapeutic substance may be brought in contact with the nerve and/or allowed to coat the nerve.
  • the step of positioning the scaffold is performed upon exposure of the nerve during surgery.
  • the therapeutic substance is dexamethasone.
  • the therapeutic substance comprises a formulation comprising a biodegradable carrier and a therapeutic ingredient advantageous during tonsillectomy or sinus surgery.
  • the therapeutic ingredient comprises a local anaesthetic.
  • the therapeutic ingredient comprises an anti-inflammatory agent.
  • the therapeutic ingredient comprises an antibiotic.
  • the therapeutic ingredient comprises a haemostatic agent.
  • the therapeutic substance comprises a formulation comprising a biodegradable carrier and a therapeutic ingredient advantageous in treatment of burns or skin loss.
  • the therapeutic substance comprises a formulation comprising a biodegradable carrier and a chemotherapy agent.
  • Positioning of a chemotherapy agent during surgery allows for work around vital structures. For example when a cancer is located around a significant nerve the surgeon will wish to avoid damaging the nerve.
  • the method allows for a long acting chemotherapy agent to be left on a tumour or evidence of residual disease for long term treatment.
  • a system comprising a solid phase biodegradeable scaffold with a therapeutic substance loaded thereon.
  • the scaffold further is further loaded with a haemostatic agent.
  • the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
  • the therapeutic substance is dexamethasone.
  • the carrier on which the therapeutic ingredient is loaded onto the scaffold is adapted to allow for ease of application of the therapeutic substance and associated pharmacological ingredient to a designated site during surgery and for concentration and efficiency.
  • the carrier is, in some forms, adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended. In some forms the carrier is adapted to localise the active pharmacological ingredient to the site at which its effect is intended.
  • the process allows controlled application of a therapeutic substance directly to a location such as a nerve, a burn site, a surgical site or a cancer.
  • the application can limit or prevent peripheral damage, trauma or injury occurring during surgery and limit flow of the therapeutic substance beyond the intended site.
  • the step of applying the scaffold loaded with the therapeutic substance to the nerve is performed upon exposure of the nerve during surgery.
  • the step of applying a therapeutic substance to the nerve is performed using a delivery device comprising a reservoir and an outlet, the therapeutic substance being delivered through the outlet.
  • actuation of the delivery device effects delivery of the formulation during the time at which the actuator is actuated.
  • the carrier in some forms is adapted to slow release, to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste.
  • the carrier in some forms, comprises natural polymers for example copolymers such as poly(lactic-co-glycolic acid), alginate, proteins, collagens, gelatin, fibrins, hyaluronan, polysaccharides, and albumin, or other synthetic polymers.
  • natural polymers for example copolymers such as poly(lactic-co-glycolic acid), alginate, proteins, collagens, gelatin, fibrins, hyaluronan, polysaccharides, and albumin, or other synthetic polymers.
  • the formulation includes a marker such as a visual or fluorescent marker.
  • a marker such as a visual or fluorescent marker.
  • the use of a marker gives a surgeon a visual cue to indicate the presence of the formulation on a site. In some forms this enables the future identification of the labelled site and/or allows delineation of target sites.
  • Biocompatible materials used for fabrication of scaffolds for the purposes of delivery of a therapeutic substance may comprise natural polymers for example copolymers such as poly(lactic-co-glycolic acid), alginate, proteins, collagens, gelatin, fibrins, and albumin, or other synthetic polymers.
  • the polymer comprises re-oxidised cellulose.
  • bioceramics such as hydroxyapatites and tricalcium phosphates are used.
  • the structures are porous to allow delivery of drugs and genetic materials at a controlled rate over a period of time.
  • antibiotics or anti-inflammatory agents may be loaded onto the scaffold to prevent infection or inflammation after surgery.
  • the therapeutic substance is loaded through a biodegradable carrier such as hyalauronic acid for gradual sustained release.
  • a formulation comprising an active pharmacological ingredient having a neuroprotective effect and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
  • the active pharmacological ingredient is a corticosteroid.
  • the carrier is a depot matrix.
  • the formulation comprises hyaluronic acid in the form of Hyasis® 850 (10.0 mg/mL), dexamethasone sodium phosphate (4.0 mg/mL), creatinine, sodium citrate, sodium disulfite, methyl paraben, propyl paraben (pH 6.8)
  • the formulation was stored at 5, 25, and 37° C. for 210 days and the Hyaluronic Acid molecular weight was measured by SECMALS
  • FIG. 1 shows the results in graphical form.
  • the formulation was stored at 5, 25, and 37° C. for 210 days and the Hyaluronic Acid molecular weight was measured by SECMALS
  • FIG. 2 shows the results in graphical form.
  • the formulation was stored at 5, 25, and 37° C. for 91 days and drug stability was assessed by HPLC
  • FIG. 3 shows the results in graphical form.
  • the formulation was stored at 5, 25, and 37° C. for 91 days and drug stability was assessed by HPLC
  • FIG. 4 shows the results in graphical form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)

Abstract

Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery. In some aspects, disclosed is a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.

Description

BACKGROUND
The present invention relates to limiting trauma to a nerve, and to a formulation, delivery system and process for limiting trauma to a nerve. The formulation and process particularly limit the impact of surgery or other event or activity on a nerve, however the formulation and process are not limited to those applications. The delivery system is particularly suited to delivering a therapeutic substance during surgery but is not limited to that application
SUMMARY
Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery.
In some forms the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
In some forms the therapeutic substance comprises an active pharmacological ingredient and a carrier.
The process has the benefit of limiting nerve trauma for patients during surgery or dental surgery by providing a predictable localisation and consistent rate-limited delivery of an active pharmaceutical ingredient that reduces the trauma on nerves through surgery. The delivery of the active pharmaceutical ingredient directly to the nerve during surgery improves nerve function and repair post surgery.
In some aspects, disclosed is a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
The formulation includes an active pharmaceutical ingredient and a carrier that provides benefits such as slow release and localisation of the active pharmaceutical. The active pharmaceutical ingredient therefore is more likely to remain on the intended site of effect.
In other aspects, disclosed is use of a formulation as described during surgery.
In some forms the use comprises applying the formulation to a nerve that has been exposed during surgery.
Disclosed in some forms is a method of delivering a therapeutic substance during surgery, the method comprising loading a solid phase or gel phase biodegradeable scaffold with a therapeutic substance; and positioning the scaffold during surgery such that the therapeutic substance is delivered to a desired location.
During surgery, internal delivery sites for therapeutic substances are exposed allowing for positioning of a scaffold to allow positioning of the material such that it remains in one place, and delivery of the substance over a period of time at a sustained rate.
In some forms the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve and the desired location is proximal to a nerve.
In some forms the method allows for delivery of a therapeutic substance and a haemostatic agent in combination.
In other aspects, disclosed is a system for delivering a therapeutic substance during surgery, the system comprising a solid phase biodegradable scaffold with a therapeutic substance loaded thereon.
The method and system may provide for improved levels of pain management, improved delivery of the therapeutic substance, improved recovery, improved muscle function, improved autonomy, or improved sensation. In some forms chronic pain or inflammation can be reduced or avoided. In some forms delivery of the drug beyond a selected site is minimised.
In some forms the method of delivery allows differentiation of delivery of different therapeutic substances.
In some forms, disclosed is a formulation comprising an active pharmacological ingredient having a neuroprotective effect and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
In some forms, disclosed is a process of protecting a nerve during surgery, the process comprising identifying a nerve using a nerve monitor and applying a therapeutic substance to the nerve. In some form the process further comprises the step of monitoring the nerve function by monitoring EMG activity from muscles innervated by the affected nerve.
The process, formulation and delivery system may provide for improved levels of pain, improved recovery, improved muscle function, improved autonomy, or improved sensation. In some forms chronic pain or inflammation can be reduced or avoided. They may provide for improved effectiveness of treatment.
BRIEF DESCRIPTION OF THE FIGURES
The disclosure will be described in view of the Figures,
FIG. 1 is a graphical representation of molecular weight v time for hyaluronic acid with dexamethasone as in some embodiments of the disclosure;
FIG. 2 is a graphical representation of molecular weight v time for hyaluronic acid with dexamethasone as in some embodiments of the disclosure;
FIG. 3 graphical representation of drug stability v time for dexamethasone in the presence of excipients as in some embodiments of the disclosure;
FIG. 4 is a graphical representation of drug stability v time for dexamethasone with hyaluronic acid as in some embodiments of the disclosure.
 DETAILED DESCRIPTION OF EMBODIMENTS OF THE DISCLOSURE
Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery.
In some forms the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve. In some forms the formulation interrupts or downregulates intra-axonal pathways of cell death or degradation during the course of a surgical procedure. In some forms the therapeutic substance has a neuroprotective effect.
In some forms the therapeutic substance comprises an active pharmacological ingredient and a carrier.
In some forms the carrier is a depot matrix. In some forms the carrier is adapted to slow the release of the active pharmacological ingredient.
In some forms the carrier has a consistency and rheology adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
In some forms the carrier is adapted to localise the active pharmacological ingredient to the site at which its effect is intended.
In some forms the active pharmacological ingredient is a corticosteroid. In some forms the pharmacological ingredient is dexamethasone.
In some forms the active pharmacological ingredient is hydrocortisone, methylprednisone, triamcinolone, Betamethasone or any other corticosteroid.
In some forms the active pharmacological ingredient is any of a number of medications which have a neuroprotective effect or act to decrease nerve dysfunction. This may include any one or more of 4-Aminopyridine (or derivatives eg. Fampridine), Riluzole, NAD altering molecules such as nicotinamide mononucleotide, CD38 and cyclic ADP ribose hydrolase inhibitors, nicotinomide riboside, AICAR, resveratrol, thiazolidinediones (eg. rosiglitazone, pioglitazone etc), metformin, local anaesthetics (eg. bupivicaine), cyclosporin, tacrolimus, COX inhibitors (eg. ketorolac, diclofenac), calcium channel blockers (eg. nifedipine), pipaverine, dexpramiprexole.
In some forms the active pharmacological acts by improving mitochondrial function or inhibiting calcium or cell death pathways.
Surgical nerve injury peripheral to the surgery is a danger of surgery. Nerve dysfunction can result from trauma to the nerves despite the nerves appearing to be intact. This makes nerve dysfunction difficult to predict during surgery. Traumatic mechanisms such as stretch, thermal injury, electrical injury, compression and ischaemia can accumulate to cause activation of pathways of cellular degradation within a nerve's axon. This can cause nerve break down and loss of function.
The process of controlled application of a formulation directly to a nerve that can intervene in pathways of cellular degradation has the impact of reducing the potential of trauma to the nerve or reducing the effects of that trauma. This trauma can occur even in circumstances where that trauma is not visible. Thus application of dexamethasone or an alternative active pharmaceutical ingredient to a nerve during surgery can limit or prevent peripheral nerve injury occurring during surgery.
In some forms the step of applying a therapeutic substance to the nerve is performed upon exposure of the nerve during surgery.
In some forms, the step of applying a therapeutic substance to the nerve is performed using a delivery device comprising a reservoir and an outlet, the therapeutic substance being delivered through the outlet.
In some forms actuation of the delivery device effects delivery of the formulation during the time at which the actuator is actuated.
Further, disclosed is a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to slow release to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended.
In some forms the active pharmacological ingredient is effective to limit nerve dysfunction or have a neuroprotective impact.
The active pharmaceutical ingredient may also include a prodrug, biologic, immunoglobulin, viral vector, gene therapy, immunotherapy, DNA plasmid, RNA inhibitor or protein or peptide.
The formulation allows the application of an active pharmaceutical ingredient to a nerve while limiting the application of that ingredient to surrounding cells. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste. The formulation can also act to slow release of the active pharmaceutical ingredient.
The formulation, in some embodiments of the disclosure, comprises a corticosteroid such as dexamethasone in the form of dexamethasone phosphate or dexamethasone sodium phosphate in hyaluronic acid. In some forms the formulation comprises dexamethasone sodium phosphate, in a hydrogel of hyaluronic acid. In some forms the formulation further includes any one of more of the excipients creatinine, sodium citrate, sodium sulphate, methyl paraben, propylparaben. In some forms the hyaluronic acid may be cross-linked using a process such as divinyl sulfone or similar cross-linking technology. In some forms the hyaluronic acid may be esterified.
In some forms, the formulation includes a marker such as a visual or fluorescent marker. Example markers could include biocompatible excipients or food dyes such as brilliant blue (FD&C Blue #1), indigo carmine or similar, antioxidants such as ascorbic acid, fluorescent markers such as Fluorescein, indocyanine green (ICG), protoporphyrin IX or other surgical dyes such as patent blue V, trypan blue, isosulfan blue or methylene blue. The use of a marker gives a surgeon a visual cue to indicate the presence of the formulation on a nerve. This may aid the user in applying the formulation under-vision and to prevent repeated dosing over the same site. In some forms this enables the future identification of the labelled nerve and/or allows intra-axonal transport to delineate target organs or cell bodies for a particular nerve.
Also disclosed is use of a formulation as described during surgery. In some forms the use comprises applying the formulation to a nerve that has been exposed during surgery.
Disclosed is some forms is a composition comprising hyaluronic acid and dexamethasone. The composition in some forms is for use in the treatment and protection of nerves during surgery.
In some forms the hyaluronic acid is in the concentration of between 1% and 3% w/w. In some forms the concentration of hyaluronic acid is between approximately 10 mg/mL and 50 mg/mL, in some forms the concentration is 30 mg/mL.
In some forms the hyaluronic acid is in the form of sodium hyaluronate with a Molecular weight of 0.9 MDa (0.8-1.0) or a molecular weight of 2.1 MDa (2.0-2.3 MDa) But may be within the range 7 to 2300 kDa.
In some forms the formulation comprises hyaluronic acid with a substantially consistent molecular weight of approximately 0.9 MDa or a substantially consistent molecular weight of approximately between 0.8 and 1.0 MDa. In this form the formulation may have a concentration of approximately 5% w/w. In this form the formulation may include dexamethasone at a concentration of approximately 1 mg/mL.
In some forms the formulation comprises hyaluronic acid with a substantially consistent molecular weight of approximately 2.1 MDa or a substantially consistent molecular weight of approximately between 2.0 and 3.0 MDa. In this form the formulation may have a concentration of approximately 3% w/w. In this form the formulation may also include dexamethasone at a concentration of approximately 1 mg/mL.
In some forms the carrier may be an oligosaccharide of sodium hyaluronate. In some forms the carrier may be a sodium hyaluronate nanofiber or microfiber.
In some forms, the carrier has a consistent molecular weight and a consistent concentration. A consistent molecular weight in combination with a consistent concentration results in a reproducible viscosity and rheology.
In some forms the dexamethasone is in the form of dexamethasone phosphate. In some forms the dexamethasone phosphate is in the concentration of between 0.1 mg/mL and 10.0 mg/mL. In some forms the dexamethasone phosphate is in the concentration of approximately 1 mg/mL. In some forms the dexamethasone phosphate is in a concentration of 4 mg/mL.
In some forms the hyaluronic acid has a weight percentage between 0.5% and 5% w/w. In some forms the weight percentage of hyaluronic acid in the formulation is between 1% and 3%. In some forms the weight percentage of hyaluronic acid in the formulation is approximately 2%.
In some forms the dexamethasone is in the form of dexamethasone sodium phosphate. In some forms the dexamethasone sodium phosphate is in the concentration of between 0.5 mg/mL and 4.0 mg/mL. In some forms the dexamethasone sodium phosphate is in the concentration of approximately 1 mg/mL.
In some forms the composition further comprises one or more of creatinine, sodium citrate, sodium disulfite, methyl paraben, propyl paraben.
Further disclosed is use of a composition comprising hyaluronic acid and dexamethasone in the manufacture of a medicament for treatment and protection of nerves during surgery.
Disclosed is a method of treatment of an exposed nerve comprising delivering a composition comprising:
a matrix having one or more of a slow release effect and a viscosity that encourages maintenance of the location of the composition in the delivery location and
a pharmacological active having one or more of a neuroprotective effect and a reduction of nerve dysfunction;
to an exposed nerve.
In some forms the matrix comprises a partially cross-linked hyaluronan hydrogel. In some forms the matrix has a pH=6.9-7.5. In some forms the hyaluronic acid has a concentration of approximately 1.5-2.0% w/w.
In some forms the rheology of the matrix limits the flow of the active away from a site of delivery. In some forms this allows for extended therapeutic effects. In some forms the elastic modulus of the matrix is between 100-200 Pa.
In some forms the carrier or matrix is adapted to slow release, to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste.
In some forms the method comprises using a delivery device to deliver the composition.
In some forms the method is used in conjunction with a nerve monitor to enhance the process of locating a particular nerve and allow accurate deposit of the therapeutic formulation to the nerve. This provides a complete nerve solution by utilising both a diagnostic tool and a therapeutic formulation to treat and protect a nerve. Nerve monitors enable surgeons to identify, confirm, and monitor motor nerve function to help reduce the risk of nerve damage during various procedures.
Disclosed in some forms is a process for delivering a therapeutic substance during surgery. The method comprises loading a solid phase biodegradable scaffold with a therapeutic substance; positioning the scaffold during surgery such that the therapeutic substance is delivered to a desired location.
In some forms the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
In some forms the desired location is proximal or adjacent to a nerve. In some forms the therapeutic substance may be brought in contact with the nerve and/or allowed to coat the nerve.
In some forms the step of positioning the scaffold is performed upon exposure of the nerve during surgery.
In some forms the therapeutic substance is dexamethasone.
In some forms the therapeutic substance comprises a formulation comprising a biodegradable carrier and a therapeutic ingredient advantageous during tonsillectomy or sinus surgery.
In some forms the therapeutic ingredient comprises a local anaesthetic.
In some forms the therapeutic ingredient comprises an anti-inflammatory agent.
In some forms the therapeutic ingredient comprises an antibiotic.
In some forms the therapeutic ingredient comprises a haemostatic agent.
In some forms the therapeutic substance comprises a formulation comprising a biodegradable carrier and a therapeutic ingredient advantageous in treatment of burns or skin loss.
In some forms the therapeutic substance comprises a formulation comprising a biodegradable carrier and a chemotherapy agent.
Positioning of a chemotherapy agent during surgery allows for work around vital structures. For example when a cancer is located around a significant nerve the surgeon will wish to avoid damaging the nerve. The method allows for a long acting chemotherapy agent to be left on a tumour or evidence of residual disease for long term treatment.
Further, disclosed is a system comprising a solid phase biodegradeable scaffold with a therapeutic substance loaded thereon.
In some forms the scaffold further is further loaded with a haemostatic agent.
In some forms the therapeutic substance is selected from substances that can intervene in the activation of pathways of cellular degradation within the nerve.
In some forms the therapeutic substance is dexamethasone.
In some forms the carrier on which the therapeutic ingredient is loaded onto the scaffold is adapted to allow for ease of application of the therapeutic substance and associated pharmacological ingredient to a designated site during surgery and for concentration and efficiency. The carrier is, in some forms, adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended. In some forms the carrier is adapted to localise the active pharmacological ingredient to the site at which its effect is intended.
The process allows controlled application of a therapeutic substance directly to a location such as a nerve, a burn site, a surgical site or a cancer. The application can limit or prevent peripheral damage, trauma or injury occurring during surgery and limit flow of the therapeutic substance beyond the intended site.
In some forms the step of applying the scaffold loaded with the therapeutic substance to the nerve is performed upon exposure of the nerve during surgery.
In some forms, the step of applying a therapeutic substance to the nerve is performed using a delivery device comprising a reservoir and an outlet, the therapeutic substance being delivered through the outlet.
In some forms actuation of the delivery device effects delivery of the formulation during the time at which the actuator is actuated.
The carrier in some forms is adapted to slow release, to prolong the pharmacokinetics of the active pharmaceutical, and to reduce dissemination of the active pharmaceutical ingredient beyond the site at which its effect is intended. This may provide greater concentration of the active pharmaceutical to the relevant cells and limits waste.
The carrier, in some forms, comprises natural polymers for example copolymers such as poly(lactic-co-glycolic acid), alginate, proteins, collagens, gelatin, fibrins, hyaluronan, polysaccharides, and albumin, or other synthetic polymers.
In some forms, the formulation includes a marker such as a visual or fluorescent marker. The use of a marker gives a surgeon a visual cue to indicate the presence of the formulation on a site. In some forms this enables the future identification of the labelled site and/or allows delineation of target sites.
The process and system are specifically described in relation to delivery of a formulation that can intervene in pathways of cellular degradation of a nerve or be used in treatment during tonsillectomy or sinus surgery, in treatment of burns or skin loss or in treatment of cancer through a chemotherapy agent during surgery. However it will be clear that the process of delivery can be utilised beyond the described circumstances.
Biocompatible materials used for fabrication of scaffolds for the purposes of delivery of a therapeutic substance may comprise natural polymers for example copolymers such as poly(lactic-co-glycolic acid), alginate, proteins, collagens, gelatin, fibrins, and albumin, or other synthetic polymers. In some forms the polymer comprises re-oxidised cellulose. In other forms bioceramics such as hydroxyapatites and tricalcium phosphates are used.
The structures are porous to allow delivery of drugs and genetic materials at a controlled rate over a period of time.
In some forms antibiotics or anti-inflammatory agents may be loaded onto the scaffold to prevent infection or inflammation after surgery.
In some forms the therapeutic substance is loaded through a biodegradable carrier such as hyalauronic acid for gradual sustained release.
Disclosed in some forms is a formulation comprising an active pharmacological ingredient having a neuroprotective effect and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
In some forms the active pharmacological ingredient is a corticosteroid.
In some forms the carrier is a depot matrix.
EXAMPLES
The following formulations are exemplary only and other formulations with alternative carriers, alternative active pharmaceuticals, alternative excipients and alternative concentrations will fall inside the scope of the claims and the scope of the disclosure.
Example 1
In the first example the formulation comprises hyaluronic acid in the form of Hyasis® 850 (10.0 mg/mL), dexamethasone sodium phosphate (4.0 mg/mL), creatinine, sodium citrate, sodium disulfite, methyl paraben, propyl paraben (pH 6.8)
The formulation was stored at 5, 25, and 37° C. for 210 days and the Hyaluronic Acid molecular weight was measured by SECMALS
Results
No significant polymer degradation was observed up to 210 days at 5 and 25° C.
Significant degradation was observed after 18 days at 37° C. most likely due to one or several excipients and/or their degradation products and the degradation products of dexamethasone (according to control experiments)
FIG. 1 shows the results in graphical form.
Example 2
Formulation: hyaluronic acid (10.0 mg/mL), dexamethasone sodium phosphate (4.0 mg/mL) (pH 6.8)
The formulation was stored at 5, 25, and 37° C. for 210 days and the Hyaluronic Acid molecular weight was measured by SECMALS
Results
No hyaluronic acid degradation was observed up to 210 days at 5 and 25° C. Dexamethasone and/or its degradation products most likely resulted in significant hyaluronic acid degradation after 30 days at 37° C.
FIG. 2 shows the results in graphical form.
Example 3
Formulation
Dexamethasone sodium phosphate (4.0 mg/mL), creatinine, sodium citrate, sodium disulfite, methyl paraben, propyl paraben (pH 6.8)
The formulation was stored at 5, 25, and 37° C. for 91 days and drug stability was assessed by HPLC
Results:
No drug degradation was observed up to 91 days at 5 and 25° C. Heat and/or one or several excipients and/or their degradation products most likely resulted in significant API degradation after 28 days at 37° C.
FIG. 3 shows the results in graphical form.
Example 4
Formulation: hyaluronic acid (10.0 mg/mL), dexamethasone sodium phosphate (4.0 mg/mL) (pH 6.8)
The formulation was stored at 5, 25, and 37° C. for 91 days and drug stability was assessed by HPLC
Results:
No drug degradation was observed up to 91 days at all Temperatures.
FIG. 4 shows the results in graphical form.
Example 5
Sodium Hyaluronate 3%+Dexamethosone 1 mg/ml+Brilliant Blue FCF (FD&C Blue #1).
Example 6
Sodium Hyaluronate 5%+Dexamethasone 2 mg/ml+Isosulfan Blue.
Example 7
Sodium Hyaluronate 5%+Dexamethasone 2 mg/ml+Fluroscien
Example 8
Sodium hyaluronate 3%+Dexamethasone 1 mg/ml+polyglycolic acid polymer (dyed)
Example 9
Sodium Hyaluronate 2%+Nicotinomide Mononucleotide (NMN)
Example 10
Sodium Hyaluronate 3%+Dexamethasone+Nicotinomide Mononucleotide (NMN)
Example 11
Sodium Hyaluronate 2%+Nicotinomide riboside
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
In the claims which follow and in the preceding description of the disclosure, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

Claims (8)

What is claimed is:
1. A method for protection of one or more nerves during surgery, the method comprising the successive steps of:
A) performing surgery including making an incision, a length of a nerve being exposed by the incision, the length of the nerve being able to be identified visually;
B) visually identifying the length of the exposed nerve;
C) applying a formulation directly along the length of the exposed nerve, the formulation comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the one or more nerves, and a carrier adapted to localise application of the formulation to the exposed length of the nerve and reduce dissemination of the active pharmacological ingredient beyond the exposed length of the nerve; and
D) closing the incision made in step A).
2. A method as defined in claim 1, wherein the formulation is in a flowable form and comprises an active pharmacological ingredient and a carrier.
3. A method as defined in claim 2 wherein the carrier is a depot matrix.
4. A method as defined in claim 2, wherein the carrier is adapted to slow the release of the active pharmacological ingredient.
5. A process of protecting a nerve during surgery, the process comprising the successive steps of:
A) performing surgery including making an incision, a length of nerve being exposed by the incision, the length of nerve exposed being able to be visually identified,
B) identifying the exposed nerve,
C) applying a formulation directly along the exposed length of the nerve, the formulation comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve, and a carrier adapted to localise application of the formulation to the exposed nerve and reduce dissemination of the active pharmacological ingredient beyond the nerve, and
D) closing the incision made in step A).
6. A process as defined in claim 5, further comprising the step of monitoring the nerve function by monitoring EMG activity from muscles innervated by the exposed nerve.
7. A process as defined in claim 5, wherein the step of identifying a nerve is performed using a nerve monitor.
8. A process as defined in claim 5, wherein the formulation is in a flowable form when applied to the nerve.
US15/579,224 2015-06-02 2016-06-02 Formulation and process for limiting nerve trauma Active US11324758B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2015902089 2015-06-02
AU2015902089A AU2015902089A0 (en) 2015-06-02 Formulation and device for limiting nerve trauma
AU2015902669A AU2015902669A0 (en) 2015-07-07 Method and system for delivering a therapeutic substance during surgery
AU2015902669 2015-07-07
AU2015903087A AU2015903087A0 (en) 2015-08-03 Delivery Device
AU2015903087 2015-08-03
PCT/AU2016/050445 WO2016191820A1 (en) 2015-06-02 2016-06-02 Formulation and process for limiting nerve trauma

Publications (2)

Publication Number Publication Date
US20180185390A1 US20180185390A1 (en) 2018-07-05
US11324758B2 true US11324758B2 (en) 2022-05-10

Family

ID=57439760

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/579,224 Active US11324758B2 (en) 2015-06-02 2016-06-02 Formulation and process for limiting nerve trauma
US15/577,999 Active 2037-01-21 US11857554B2 (en) 2015-06-02 2016-06-02 Drug delivery device with pre-assembled cartridge

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/577,999 Active 2037-01-21 US11857554B2 (en) 2015-06-02 2016-06-02 Drug delivery device with pre-assembled cartridge

Country Status (8)

Country Link
US (2) US11324758B2 (en)
EP (2) EP3302653A4 (en)
JP (1) JP2018516910A (en)
CN (1) CN107635604A (en)
AU (4) AU2016269847A1 (en)
CA (2) CA2986937A1 (en)
HK (2) HK1253778A1 (en)
WO (2) WO2016191820A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
WO2017139487A1 (en) 2016-02-09 2017-08-17 Northwind Medical, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
WO2018005848A1 (en) 2016-06-29 2018-01-04 Bright, Corinne Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US20210315587A1 (en) 2018-07-02 2021-10-14 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap with rapid release
CN117599244A (en) 2018-07-02 2024-02-27 图拉维治疗股份有限公司 Method and apparatus for forming nerve caps in situ
KR102501175B1 (en) * 2020-02-03 2023-02-16 엠앤에이치바이오 주식회사 Controlled release formulations for treating hearing loss and method of preparing the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238702B1 (en) 1992-09-10 2001-05-29 Children's Medical Center Corp. High load formulations and methods for providing prolonged local anesthesia
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
WO2008157057A2 (en) 2007-06-19 2008-12-24 Warsaw Orthopedic, Inc. Locally administrated low doses of corticosteroids
US20090263456A1 (en) 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US8190271B2 (en) 2007-08-29 2012-05-29 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
WO2014116876A1 (en) 2013-01-23 2014-07-31 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
WO2016118649A1 (en) 2015-01-21 2016-07-28 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2221739A (en) * 1939-10-16 1940-11-12 Reiter David Hypodermic syringe
US2669230A (en) * 1947-07-30 1954-02-16 Becton Dickinson Co Injection apparatus
US3496937A (en) * 1967-05-18 1970-02-24 John E Balson Hypodermic syringe
ATE19203T1 (en) 1981-11-12 1986-05-15 John Joseph Jacklich DENTAL SYRINGE.
US4641766A (en) * 1984-11-02 1987-02-10 Alcon Laboratories, Inc. Metering dispenser for high viscosity compositions
US4659327A (en) * 1985-11-26 1987-04-21 Dentsply Research & Development Corp. Multiple dosage syringe
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
GB2369996B (en) * 2000-12-18 2004-06-23 S T D Pharmaceutical Products Method and apparatus for producing an injectable foam
US9205197B2 (en) * 2003-03-03 2015-12-08 Sanofi-Aventis Deutschland Gmbh Drug delivery device dose setting mechanism
EP2040780B1 (en) 2006-07-03 2016-01-06 Novo Nordisk A/S Coupling for injection devices
CN201033195Y (en) * 2007-01-29 2008-03-12 吴同顺 Automatic needle inserting device of the injection syringe
EP2340070B1 (en) 2008-09-10 2014-07-02 F. Hoffmann-La Roche AG Delivery device for use with a therapeutic drug
CA2749775A1 (en) * 2009-01-30 2010-08-05 Sanofi-Aventis Deutschland Gmbh Cartridge and medication delivery device
CN102869399B (en) * 2010-03-09 2015-06-24 Shl集团有限责任公司 Medicament delivery device
EP2603264A1 (en) 2010-08-12 2013-06-19 Covidien LP Single use device for delivery of cartridge drugs
CA2807991A1 (en) 2010-08-13 2012-03-16 Sanofi-Aventis Deutschland Gmbh Connector for a drug delivery device reservoir
AU2011290668B2 (en) 2010-08-19 2014-08-14 Novo Nordisk A/S Medical auto-injection device for manual needle insertion having needle shield, damping mechanism and audible and tactile feedback
CN103702699B (en) * 2011-07-07 2016-08-17 诺沃—诺迪斯克有限公司 Drug delivery injection pen with additional dose capture and display module
CN103239780A (en) * 2012-02-14 2013-08-14 上海双鸽实业有限公司 Safety syringe needle
EP2656865A1 (en) 2012-04-24 2013-10-30 Sanofi-Aventis Deutschland GmbH Syringe carrier with needle shield and data storage device for use in a medical auto-injection device
EP2682142A1 (en) 2012-07-06 2014-01-08 Sanofi-Aventis Deutschland GmbH Autoinjector
CN103894970A (en) * 2012-12-24 2014-07-02 健康机器人技术有限公司 Device used for removing needle of injector

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238702B1 (en) 1992-09-10 2001-05-29 Children's Medical Center Corp. High load formulations and methods for providing prolonged local anesthesia
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
WO2008157057A2 (en) 2007-06-19 2008-12-24 Warsaw Orthopedic, Inc. Locally administrated low doses of corticosteroids
US8190271B2 (en) 2007-08-29 2012-05-29 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
US20090263456A1 (en) 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
WO2014116876A1 (en) 2013-01-23 2014-07-31 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
WO2016118649A1 (en) 2015-01-21 2016-07-28 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
European Patent Office Extended Search Report for Application No. 16802250.7 dated Jan. 28, 2019, 9 pages.
Ikeda et al., "Hyaluronic acid prevents peripheral nerve adhesion." Br J Plast Surg. 2003; 56(4):342-7.
International Preliminary Report on Patentability for Application No. PCT/AU2016/050445 dated Oct. 11, 2017 (36 pages).
International Search Report for Application No. PCT/AU2016/050445 dated Jul. 26, 2016 (8 pages).
Ito, T. et al., "Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone," Biomaterials, 2007, vol. 28, Issue 10, pp. 1778-1786.
Ozsoy, Z. et al., "The effect of methylprednisolone and tenoxicam on the protection of damage of the nerve physiomorphology caused by prolene mesh," International Journal of Surgery, 2015, vol. 22, pp. 159-163.

Also Published As

Publication number Publication date
EP3302491A1 (en) 2018-04-11
AU2021202821A1 (en) 2021-06-03
WO2016191819A1 (en) 2016-12-08
AU2023200759A1 (en) 2023-03-09
EP3302491A4 (en) 2019-02-27
CA2986447A1 (en) 2016-12-08
US20180154080A1 (en) 2018-06-07
US20180185390A1 (en) 2018-07-05
EP3302653A4 (en) 2019-02-20
AU2016269847A1 (en) 2017-12-07
WO2016191820A1 (en) 2016-12-08
CN107635604A (en) 2018-01-26
CA2986937A1 (en) 2016-12-08
HK1253778A1 (en) 2019-07-05
US11857554B2 (en) 2024-01-02
HK1253582A1 (en) 2019-06-21
EP3302653A1 (en) 2018-04-11
AU2016269848A1 (en) 2017-11-30
AU2016269848B2 (en) 2021-12-09
JP2018516910A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US11324758B2 (en) Formulation and process for limiting nerve trauma
Seo et al. Injectable intratumoral hydrogel as 5-fluorouracil drug depot
US9040062B2 (en) Preparation for treatment of spinal cord injury
JP6869902B2 (en) Implantable drug delivery composition and its usage
Asfour et al. Chitosan/β-glycerophosphate in situ forming thermo-sensitive hydrogel for improved ocular delivery of moxifloxacin hydrochloride
EP2968693B1 (en) Materials for gastrointestinal obstruction prevention
AU2018229478A1 (en) Biodegradable, active ingredient-eluting structural support
EP1962798A1 (en) Injectable formulation capable of forming a drug-releasing device
ES2727273T3 (en) Thioxanthin-based autophagy-inhibiting therapies to treat cancer
US10799289B2 (en) Compositions, systems, kits, and methods for neural ablation
CN101820876A (en) Method of treating acute pain using a formulated drug depot in combination with a liquid formulation
Shoichet et al. Intrathecal drug delivery strategy is safe and efficacious for localized delivery to the spinal cord
CN105934242A (en) Microparticles for in vivo administration via medical catheters
US20210060316A1 (en) Submucosal bioresorbable drug eluting platform
BR112019026225A2 (en) polymeric paste compositions for drug release
Elhabal et al. Nano-spanlastics-loaded dissolving microneedle patches for ketotifen fumarate: advanced strategies for allergic conjunctivitis treatment and molecular insights
JP2018516910A5 (en)
Li et al. Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery
CN109152868A (en) Prevent biological tissue's adhesion
US20230225963A1 (en) Thermogel sustained-release microparticle-based delivery to a paranasal and/or nasal cavity
Liu et al. Orthopedic implants of ketorolac in vertebral fracture: Development, physicochemical, preclinical and clinical evaluation
US20220054405A1 (en) Submucosal bioresorbable drug eluting platform
Neamah et al. Intravitreal implantable film containing ketorolac tromethamine microsponges in vitro/in vivo correlation
Duci Justification of the topical use of pharmacological agents on reduce of tendon adhesion after surgical repair
Elyasi et al. Adhesion prevention by peritoneal administration of herbal hydrogel

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: NEWSOUTH INNOVATIONS PTY LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EVISTON, TIMOTHY J;KRISHNAN, ARUN;SIGNING DATES FROM 20171025 TO 20171028;REEL/FRAME:044852/0589

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

AS Assignment

Owner name: INTRAVITAL PTY LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEWSOUTH INNOVATIONS PTY LTD;REEL/FRAME:052087/0279

Effective date: 20190501

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4